In re: Valsartan, Losartan, and Irbesartan Products Liability Litigation, Case No. 1:19‑md‑02875‑RBK‑SAK, is pending in the U.S. District Court for the District of New Jersey. Plaintiffs claim defendants (a complete list is provided in the referenced materials) violated state law by producing, distributing, selling or dispensing Valsartan or VCDs contaminated with nitrosamine impurities—NDMA and NDEA—alleged probable human carcinogens. Defendants dispute the allegations, deny liability, contend the detected NDMA/NDEA levels were not or could not be carcinogenic, and have raised various legal and factual defenses.